伊马替尼相关肿瘤溶解综合征在一名伴有嗜酸性粒细胞增多和血小板衍生生长因子受体A（PDGFRA）重排的髓系肿瘤患者中的病例报告及文献复习 - Suppr

Suppr

超能文献

Imatinib-Associated Tumor Lysis Syndrome in a Patient With Myeloid Neoplasm With Eosinophilia and PDGFRA Rearrangement: A Case Report and Review of the Literature.

作者信息

Socola Francisco, Hawes Veronica, Lobo Rodolfo Henrich, Sasapu Appalanaidu

机构信息

All authors: University of Arkansas for Medical Sciences, Little Rock, AR.

出版信息

J Glob Oncol. 2018 Sep;4:1-4. doi: 10.1200/JGO.2016.007716. Epub 2017 Feb 8.

DOI:10.1200/JGO.2016.007716

PMID:30241197

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6180791/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64b2/6180791/07c9021f8ba1/JGO.2016.007716f1.jpg

相似文献

Imatinib-Associated Tumor Lysis Syndrome in a Patient With Myeloid Neoplasm With Eosinophilia and PDGFRA Rearrangement: A Case Report and Review of the Literature.

J Glob Oncol. 2018 Sep;4:1-4. doi: 10.1200/JGO.2016.007716. Epub 2017 Feb 8.

Myeloid Neoplasm With Eosinophilia and FIP1L1-PDGFRA Rearrangement Treated With Imatinib Mesylate: A Pediatric Case With Long-term Follow-up.

J Pediatr Hematol Oncol. 2019 May;41(4):334-335. doi: 10.1097/MPH.0000000000001446.

Int J Clin Exp Pathol. 2015 May 1;8(5):5812-20. eCollection 2015.

Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase.

Leukemia. 2013 Nov;27(11):2254-6. doi: 10.1038/leu.2013.129. Epub 2013 Apr 25.

A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: an unusual presentation of a rare disease.

Am J Surg Pathol. 2013 Jan;37(1):147-51. doi: 10.1097/PAS.0b013e31826df00b.

Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy.

Eur J Haematol. 2014 Jun;92(6):541-5. doi: 10.1111/ejh.12272. Epub 2014 Feb 19.

Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation.

Am J Hematol. 2016 Mar;91(3):E10-1. doi: 10.1002/ajh.24273. Epub 2016 Jan 11.

A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report.

Pol Arch Med Wewn. 2009 Dec;119(12):838-41.

PDGFRᵝ-Rearranged Myeloid Neoplasm with Marked Eosinophilia in a 37-Year-Old Man; And a Literature Review.

Am J Case Rep. 2017 Feb 17;18:173-180. doi: 10.12659/ajcr.900623.

Identification of a novel PDGFRA point mutation at p.P6L as a potential molecular target of imatinib in an eosinophilia patient showing genetic heterogeneity.

Cancer Biol Ther. 2019;20(4):402-407. doi: 10.1080/15384047.2018.1532558. Epub 2018 Oct 25.

本文引用的文献

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.

How I treat hypereosinophilic syndromes.

Blood. 2015 Aug 27;126(9):1069-77. doi: 10.1182/blood-2014-11-551614. Epub 2015 May 11.

World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.

Am J Hematol. 2014 Mar;89(3):325-37. doi: 10.1002/ajh.23664.

[Acute-onset eosinophilic leukemia associated with tumor lysis syndrome after imatinib and steroid pulse therapy].

Rinsho Ketsueki. 2010 May;51(5):326-31.

The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.

Haematologica. 2007 Sep;92(9):1173-9. doi: 10.3324/haematol.11420. Epub 2007 Aug 1.

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.

Blood. 2007 Jun 1;109(11):4635-40. doi: 10.1182/blood-2006-10-050054. Epub 2007 Feb 13.

FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.

Leuk Res. 2006 Aug;30(8):965-70. doi: 10.1016/j.leukres.2005.11.011. Epub 2006 Jan 6.

FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.

Blood. 2004 Nov 15;104(10):3038-45. doi: 10.1182/blood-2004-03-0787. Epub 2004 Jul 29.

Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate.

Leuk Res. 2002 Sep;26(9):881-4. doi: 10.1016/s0145-2126(02)00046-2.

Treatment of hypereosinophilic syndrome with imatinib mesilate.

Lancet. 2002 May 4;359(9317):1577-8. doi: 10.1016/S0140-6736(02)08505-7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Imatinib-Associated Tumor Lysis Syndrome in a Patient With Myeloid Neoplasm With Eosinophilia and PDGFRA Rearrangement: A Case Report and Review of the Literature.

作者信息

Socola Francisco, Hawes Veronica, Lobo Rodolfo Henrich, Sasapu Appalanaidu

机构信息

All authors: University of Arkansas for Medical Sciences, Little Rock, AR.

出版信息

J Glob Oncol. 2018 Sep;4:1-4. doi: 10.1200/JGO.2016.007716. Epub 2017 Feb 8.

DOI:10.1200/JGO.2016.007716

PMID:30241197

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6180791/

Abstract

摘要